Cardiac Effects of CAR-T and Bispecific Therapies: What Follow-Up Should Cover
Cytokine release syndrome, arrhythmia, and transient ventricular dysfunction after cellular and bispecific therapy — what resolves, what warrants longer-term cardiac follow-up, and who should own it.
Cellular and bispecific therapies have a cardiac profile driven largely by cytokine release rather than by the cumulative-dose logic familiar from anthracyclines. That changes both the acute management and the shape of follow-up.
The acute picture
Cytokine release syndrome produces fever, vasodilatation, tachycardia, and hypotension, and in more severe grades can be accompanied by arrhythmia and reduced ventricular function. Severity of the syndrome tracks reasonably well with the likelihood of a cardiac event, so grading is the practical trigger for cardiac involvement.
Management is grade-directed and led by the treating team, with cardiology involved for haemodynamic compromise, significant arrhythmia, or a fall in ejection fraction.
Who needs a thorough baseline
Patients with pre-existing heart failure, coronary disease, significant valve disease, prior anthracycline exposure, or prior chest radiation benefit most from baseline echocardiography, an electrocardiogram, and a documented risk-factor review before therapy. Reduced reserve is what turns a tolerable cytokine event into a cardiac one.
Correct anaemia, electrolytes, and uncontrolled hypertension beforehand where the schedule allows.
What follow-up should cover
Much of the transient ventricular dysfunction recovers, but recovery should be documented rather than assumed, with repeat imaging after the acute phase in anyone who had a measurable fall. Persistent arrhythmia, unrecovered function, or new symptoms warrant ongoing cardiology follow-up.
Longer-term data are still maturing, so patients with prior cardiotoxic exposure plus a cellular therapy event are reasonable candidates for a defined surveillance interval rather than discharge.
Owning the plan
Name who repeats the imaging, who reviews it, and what the interval is at the point of discharge from the acute service. This is exactly the handover that goes missing when a patient returns to a referring centre or to primary care.
Frequently asked questions
- Does CAR-T therapy affect the heart?
- It can. Most cardiac effects occur around cytokine release syndrome and include tachycardia, hypotension, arrhythmia, and transient reductions in ventricular function, with severity tracking the grade of the syndrome.
- Is cardiac follow-up needed after CAR-T or bispecific therapy?
- Anyone with a measurable fall in function, persistent arrhythmia, or prior cardiotoxic exposure should have documented repeat imaging and a defined surveillance interval rather than discharge.